Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
Status:
Unknown status
Trial end date:
2020-08-30
Target enrollment:
Participant gender:
Summary
Ph-like ALL is a recently recognized high-risk subgroup and the optimal therapeutic
approaches are poorly characterized. Based on the pediatric-inspired,
PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label,
two-arm, multi-site trial PDT-Ph-like-ALL is aimed to evaluate the safety and effect of oral
histone deacetylase inhibitor chidamide and dasatinib for adult Ph-like ALL.